© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
December 07, 2021
Six months after a 75-year-old patient with castration-resistant prostate cancer shows undetectable PSA, the patient developed new hip pain and urinary frequency.
December 05, 2021
Oncologists discuss a 59-year-old man with poorly differentiated adenocarcinoma of the lung.
December 04, 2021
The case of a 51-year-old with multiple myeloma, standard risk, stage II was the topic of discussion during a recent Targeted Oncology Case-Based Roundtable moderated by Ajai Chari, MD.
During workup of a 59-year-old patient, an MRI of the brain showed 3 small lesions consistent with brain metastases. A bronchoscopy with transbronchial biopsy of the right lower lobe confirmed lung adenocarcinoma.
December 02, 2021
Following 6 well-tolerated cycles of R-CHOP, a 75-year-old patient with diffuse large B-cell lymphoma showed complete remission on a PET scan. But 1 year later, the disease relapsed.
Based on the case of a man with metastatic renal cell carcinoma, Brian Rini, MD, and peers discussed later-line immunotherapy and tyrosine kinase inhibitor combination therapies.
December 01, 2021
A 51-year-old man presented with worsening fatigue on exertion and pallor with an ECOG performance score of 2 and was diagnoses with stage II standard-risk multiple myeloma.
November 30, 2021
Treatment for a patient with poorly differentiated adenocarcinoma of the lung was the topic of discussion between Joshua K. Sabari, MD and peers during a Case-Based Roundtable.